Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immunologic therapeutics and diagnostics. Its therapeutic product candidates are based on its therapeutic platform and consist of REVTx-100, which is being developed for the prevention or treatment of infections, including those resulting from surgery, severe burns and antibiotic resistance; REVTx-200, which is being developed as intranasal therapy that focuses to be administered with a commercially available intramuscular (IM) vaccine; REVTx-300, which is being developed as a therapy for the treatment of chronic organ disease, including CKD and NASH; and REVTx-99b, which is being developed for the treatment of food allergies. The Company's diagnostic, REVDx-501 (REVIDTM Rapid Test Kit), is being developed as a rapid point of care or at home diagnostic product that can potentially be used to detect various respiratory viral infections.